For state-by-state regulatory and compounding context relevant to research peptides, consult the Peptide Laws by State hub.
For the regulatory discussion specific to BPC-157 and other compounds considered by the FDA advisory panel, read FDA Advisory Panel Votes to Recommend BPC-157, TB-500, KPV, and MOTS-c for Compounding.
What Is BPC-157?
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide — 15 amino acids — derived from a naturally occurring protein in human gastric juice. First isolated in the early 1990s, its stability in gastric acid and remarkable tissue-healing properties across multiple organ systems have made it one of the most extensively studied research peptides in the field.
Mechanism of Action
BPC-157 operates through several converging mechanisms. It stimulates angiogenesis by upregulating VEGFR2 and activating the FAK-paxillin pathway. It accelerates wound healing by increasing expression of growth factor receptors on fibroblasts and tendon cells. It modulates the nitric oxide system — a key regulator of blood flow, inflammation, and tissue repair — and demonstrates strong anti-inflammatory activity by suppressing COX-2 and NF-κB pathways. Uniquely, BPC-157 retains stability in gastric acid that most peptides lack.
Musculoskeletal Research
BPC-157 has been studied extensively in tendon healing models. Studies show accelerated collagen organization, fibroblast migration, and tendon tensile strength restoration following injury. Similar effects have been demonstrated in ligament, muscle, and bone healing models.
Gastrointestinal and Neurological Research
BPC-157's gastric origin gives it particular activity in the GI tract. It has demonstrated efficacy in animal models of inflammatory bowel disease, gastric ulcers, and short bowel syndrome. Neurologically, it has shown neuroprotective effects in models of traumatic brain injury, spinal cord injury, and dopaminergic system disruption.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review
Jóźwiak, M., Bauer, M., Kamysz, W., Kleczkowska, P., 2025, Pharmaceuticals - Stable Gastric Pentadecapeptide BPC 157 and Wound Healing
Seiwerth, S., Milavic, M., Vukojevic, J., et al., 2021, Frontiers in Pharmacology - Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
Hsieh, M.J., Liu, H.T., Wang, C.N., et al., 2017, Journal of Molecular Medicine - Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth
Staresinic, M., Sebecic, B., Patrlj, L., et al., 2003, Journal of Orthopaedic Research - The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
Chang, C.H., Tsai, W.C., Lin, M.S., Hsu, Y.H., Pang, J.H., 2011, Journal of Applied Physiology - Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157
Staresinic, M., Petrovic, I., Novinscak, T., et al., 2006, Journal of Orthopaedic Research - Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract
Sikiric, P., Seiwerth, S., Rucman, R., et al., 2011, Current Pharmaceutical Design - Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection
Sikiric, P., Hahm, K.B., Blagaic, A.B., et al., 2020, Gut and Liver - Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157
He, L., Feng, D., Guo, H., et al., 2022, Frontiers in Pharmacology - Pentadecapeptide BPC 157 and the central nervous system
Vukojevic, J., Milavić, M., Perović, D., et al., 2022, Neural Regeneration Research - Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats
Perovic, D., Kolenc, D., Bilic, V., et al., 2019, Journal of Orthopaedic Surgery and Research - Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds
Xu, C., Sun, L., Ren, F., et al., 2020, Regulatory Toxicology and Pharmacology